Sarepta Therapeutics, Inc. (SRPT)

NMS – Real Time Price. Currency in USD

19.13

-0.27 (-1.39%)

At close: May 12, 2026, 4:00 PM EDT

07.05.2026

Sarepta's Q1 Earnings & Sales Beat Estimates, '26 Outlook Maintained

SRPT beats Q1 earnings and revenue estimates despite a sharp Elevidys sales drop, while maintaining its 2026 product revenue outlook.

07.05.2026

Sarepta Therapeutics, Inc. (SRPT) Q1 2026 Earnings Call Transcript

06.05.2026

Sarepta Therapeutics (SRPT) Reports Q1 Earnings: What Key Metrics Have to Say

The headline numbers for Sarepta Therapeutics (SRPT) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

06.05.2026

Sarepta Therapeutics (SRPT) Q1 Earnings and Revenues Top Estimates

Sarepta Therapeutics (SRPT) came out with quarterly earnings of $3.16 per share, beating the Zacks Consensus Estimate of $0.9 per share. This compares to a loss of $3.42 per share a year ago.

06.05.2026

Sarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the first quarter 2026. "We entered 2026 with clear priorities—stabilizing the business, restoring growth, maintaining financial strength, and advancing a pipeline that we believe can define Sarepta's next era. In the first quarter, we made meaningful progress against each,” said Doug Ingram, chief executive officer, Sarept.

29.04.2026

Sarepta Therapeutics (SRPT) Reports Next Week: Wall Street Expects Earnings Growth

Sarepta Therapeutics (SRPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

22.04.2026

Sarepta Therapeutics to Announce First Quarter 2026 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2026 financial results after the Nasdaq Global Market closes on Wednesday, May 6, 2026. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss these results. The event will be webcast live under the investor relations section of Sarepta's website at https://investorrelations.sarepta.com/events-presentation.

Videos

29.07.2025

Positive

SRPT Rallies on FDA Green Light: A New Bottom for the Stock?

29.07.2025

Positive

Sarepta resumes shipping of gene therapy Elevidys to patients who can walk

25.07.2025

Neutral

Goldman Sachs' Salveen Richter on Sarepta's ongoing troubles, opportunities in biotech

21.07.2025

Negative

HC Wainwright's Kapoor talks if Sarepta shares could hit $0

Upgrades / Downgrades

Ticker	Brokerage Firm	Ratings Change	Price Target	Date
SRPT	Barclays	Equal Weight	undefined >> $22	July 29th 2025
SRPT	Bernstein	Market Perform	undefined >> $13	July 29th 2025
SRPT	H.C. Wainwright	Sell	undefined >> $5	July 29th 2025
SRPT	Oppenheimer	Outperform	undefined >> $37	July 29th 2025
SRPT	JP Morgan	Neutral	undefined >> $24	July 29th 2025
SRPT	Barclays	Underweight	undefined >> $10	July 28th 2025
SRPT	JP Morgan	Underweight	undefined >> undefined	July 25th 2025
SRPT	Citigroup	Sell	undefined >> $7	July 24th 2025

Press releases

06.05.2026

Sarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments

31.03.2026

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on March 31, 2026 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta's 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 24 individuals hired by Sarepta in the first quarter of 2026. The equity awards were approved in accordance with Nasdaq Listing Rule.

25.03.2026

Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today shared the first clinical results from two of its siRNA programs for neuromuscular diseases. Early results from Phase 1/2 ascending dose studies of SRP-1001 for facioscapulohumeral muscular dystrophy type 1 (FSHD1) and SRP-1003 for myotonic dystrophy type 1 (DM1) demonstrated dose- dependent muscle exposure, early biomarker effects, and favorable tolerab.

24.03.2026

Sarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that on Wed., March 25, 2026, at 8:30 am Eastern Time, the Company will host a webcast and conference call to present the early clinical results from the Phase 1/2 ascending dose studies of SRP-1001 for facioscapulohumeral muscular dystrophy type 1 (FSHD1) and SRP-1003 for myotonic dystrophy type 1 (DM1). The event will be webcast live under th.

Sarepta Therapeutics, Inc. (SRPT)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Sarepta Therapeutics, Inc. (SRPT)

Sarepta's Q1 Earnings & Sales Beat Estimates, '26 Outlook Maintained

Sarepta Therapeutics, Inc. (SRPT) Q1 2026 Earnings Call Transcript

Sarepta Therapeutics (SRPT) Reports Q1 Earnings: What Key Metrics Have to Say

Sarepta Therapeutics (SRPT) Q1 Earnings and Revenues Top Estimates

Sarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments

Sarepta Therapeutics (SRPT) Reports Next Week: Wall Street Expects Earnings Growth